Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the target tangible trial)

American Journal of Cardiology

Volumn 84, Issue 1, 1999, Pages 7-13

  März, Winfried ^a   Wollschläger, Helmut ^b   Klein, Gernot ^c   Neiß, Albrecht ^d   Wehling, Martin ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Städtisches Krankenhaus Amberg   (Germany)

^c Reha Clinic   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHABDOMYOLYSIS; SECONDARY PREVENTION; TREATMENT OUTCOME; VERTIGO;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; DIET, FAT-RESTRICTED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; SAFETY; SIMVASTATIN; TIME FACTORS;

EID: 0345034610     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00183-6     Document Type: Article

References (10)

1. Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
2. Blum C. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 73:1994;3D-11D.
3. Friedewald W.T., Levy R.J., Frederickson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
4. Farrington C.P., Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 9:1990;1447-1454.
5. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 6:1979;65-70.
6. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P.H., Hiratzka L.F., Houston-Miller N., Kris-Etherton P., Krumholz H.M., LaRosa J., Ockene I.S., Pearson T.A., Reed J., Smith S.C., Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease. A Statement for Healthcare Professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 95:1997;1683-1685.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
8. Dart A., Jerums G., Nicholson G., d'Emden M., Hamilton-Craig I., Tallis G., Best J., West M., Sullivan D., Bracs P., Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 80:1997;39-44.
9. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587.
10. Koren M.J., Smith D.G., Hunninghake D.B., Davidson M.H., McKenny J.M., Weiss S.R., Schrott H.G., Henley R.W. Jr, Tresh P., McLain R.W., Bakker-Arkema R.G., Black D.M. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 14:1998;59-70.